TABLE 1.
Demographic and clinical data in patients under entecavir or lamivudine treatment before bilirubin level reached >20 mg/dl
| Parameter | Value for group |
P | |
|---|---|---|---|
| Entecavir (n = 53) | Lamivudine (n = 114) | ||
| Age (yrs)a | 49 ± 13 | 43 ± 15 | 0.006 |
| Sex (M/Fb) | 38/15 | 88/26 | 0.446 |
| AST (U/liter)a | 838 ± 690 | 1,051 ± 1,010 | 0.166 |
| ALT (U/liter)a | 1,287 ± 788 | 1,629 ± 1,011 | 0.031 |
| Albumin (g/dl)a | 3.6 ± 0.6 | 3.5 ± 0.5 | 0.183 |
| Bilirubin (mg/dl)a | 6.3 ± 4.5 | 7.7 ± 5.1 | 0.087 |
| Creatinine (mg/dl)a | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.943 |
| Prothrombin time (INR)a | 1.4 ± 0.5 | 1.5 ± 0.5 | 0.308 |
| Platelet (cells × 109 /ml)a | 156 ± 59 | 175 ± 60 | 0.071 |
| HBeAg (positive/negative) | 15/38 | 47/67 | 0.123 |
| HBV DNA (×105copies/ml)a | 1,442 ± 338 | 1,642 ± 448 | 0.783 |
| Mortality | 6/53 (11.3%) | 9/114 (7.9%) | 0.325 |
a
Data presented as means ± standard deviations.
b
M, male; F, female.